Skip to main content
Premium Trial:

Request an Annual Quote

Point-of-Care Coronavirus Test From Credo Diagnostics Biomedical Gets CE Mark

NEW YORK – Credo Diagnostics Biomedical announced on Tuesday it has obtained CE mark for an assay to detect SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The test runs on the firm's point-of-care instrument and is now commercially available on countries accepting the CE designation.

The Credo platform, called VitaPCR, performs real-time PCR to detect pathogens in 20 minutes, with one minute of hands-on time. As previously reported, the system needs minimal training to run and involves no additional equipment.

Winston Wong, chairman of Singapore-based Credo, said that better tools are currently needed at front-line locations, like airports. "Rapid and accurate molecular screening [for the] COVID-19 strain will better help contain the virus and allow early actions to be taken, thus preventing tragedies," Wong said. 

The VitaPCR SARS-CoV-2 Assay is now also pending Emergency Use Authorization from the US Food and Drug Administration and Emergency Use Listing from the World Health Organization, the firm noted in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.